Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 29 July 2025 AM
A new weekly injectable for Parkinson’s disease in early development at the University of South Australia (UniSA) could prove a tough rival for companies in the space, if successfully commercialised.
The scientists have developed a sustained release formulation of levodopa and carbidopa – two key medications for Parkinson’s – that is injected under the skin or into muscle tissue, where it gradually releases the medication over seven days.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.